Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to the above referred letter, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected the Company’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14 to July 21, 2023. The Unit has now received an Establishment Inspection Report classifying the facility as ‘Voluntary Action Indicated’ (VAI).
The above information is a part of company’s filings submitted to BSE.
